Cargando…
Clinical experience of natalizumab in Crohn's disease patients in a restricted distribution program
BACKGROUND: Natalizumab (NAT) is a humanized monoclonal antibody against a4-integrin initially approved for the treatment of multiple sclerosis, and then withdrawn from the market in 2005 due to the risk of progressive multifocal leukoencephalopathy. NAT was approved for the treatment of Crohn'...
Autores principales: | Chen, Chien-Huan, Kularatna, Gowri, Stone, Christian D., Gutierrez, Alexandra M., Dassopoulos, Themistocles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hellenic Society of Gastroenterology
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959435/ |
Ejemplares similares
-
Natalizumab in the treatment of Crohn’s disease
por: Guagnozzi, Danila, et al.
Publicado: (2008) -
Natalizumab in Crohn's disease: past and future areas of applicability
por: Armuzzi, Alessandro, et al.
Publicado: (2013) -
An evidence-based review of natalizumab therapy in the management of Crohn’s disease
por: Edula, Raja GR, et al.
Publicado: (2009) -
Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn’s Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab
por: Sorrentino, Dario, et al.
Publicado: (2015) -
Clinical, Histologic, and Immunophenotypic Features of Serrated Polyps in Patients With Inflammatory Bowel Disease
por: Yang, Chen, et al.
Publicado: (2018)